UBS Group Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price

Zentalis Pharmaceuticals (NASDAQ:ZNTLFree Report) had its price target decreased by UBS Group from $5.00 to $2.20 in a research report released on Tuesday,Benzinga reports. UBS Group currently has a neutral rating on the stock.

ZNTL has been the topic of a number of other research reports. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Finally, Guggenheim dropped their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.24.

Get Our Latest Analysis on ZNTL

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $1.66 on Tuesday. The company has a market cap of $118.29 million, a price-to-earnings ratio of -0.67 and a beta of 1.86. Zentalis Pharmaceuticals has a 1 year low of $1.66 and a 1 year high of $18.07. The firm has a fifty day moving average price of $2.97 and a 200-day moving average price of $3.29.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities research analysts expect that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Erste Asset Management GmbH purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at about $37,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Aigen Investment Management LP purchased a new position in Zentalis Pharmaceuticals in the third quarter worth $41,000. Capstone Investment Advisors LLC acquired a new position in shares of Zentalis Pharmaceuticals during the third quarter worth $48,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after purchasing an additional 5,333 shares during the last quarter.

About Zentalis Pharmaceuticals

(Get Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Stories

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.